From Science to the Clinic – and Beyond
Our team works hard to drive our innovative pipeline programs into and through clinical development to assess the safety, tolerability, and immunogenicity of each candidate.
We are grateful for the many volunteers and medical experts who participate in our studies, without whom we could not reach our goal of better health for all.
Hepatitis B
Prophylactic Hepatitis B Program
Phase 3 : PROTECT
A double-blind randomized controlled trial designed to establish the non-inferiority of a 3-antigen prophylactic hepatitis B vaccine candidate compared to Engerix-B® in adults ≥ 18 years old and the superiority of a 3-antigen prophylactic hepatitis B vaccine candidate compared to Engerix-B® in ≥ 45 years old.
Status: Completed
Phase 3 : CONSTANT
A double-blind randomized controlled trial to assess the lot-to-lot consistency of a 3-antigen prophylactic hepatitis B vaccine candidate in adults.
Status: Completed
Immunotherapeutic Candidate : VBI-2601
Phase 1b/2a
Study to evaluate the safety, tolerability, and antiviral activity of VBI-2601 (BRII-179) as a component of a functional cure for chronic HBV infection, developed in partnership with Brii Biosciences.
Status: Completed
Phase 2
Study designed to evaluate the safety and efficacy of VBI-2601 (BRII-179) in combination with an HBV-targeting siRNA (VIR-2218) in adults with chronic HBV infection.
Status: Active, Not Recruiting
Phase 2a/2b
Study designed to evaluate the clinical effect of adding VBI-2601 (BRII-179) to existing standard-of-care therapy in non-cirrhotic HBV patients, developed in partnership with Brii Biosciences.
Status: Active, Not Recruiting
Glioblastoma
Immunotherapeutic Candidate : VBI-1901
Phase 1/2a
Ongoing study evaluating the safety, tolerability, and optimal dose of VBI-1901 in subjects with recurrent GBM.
Status: Active, Not Recruiting
Coronaviruses
Prophylactic Vaccine Candidates : VBI-2901, VBI-2902, and VBI-2905
Phase 1a/1b
Study to evaluate the safety, tolerability, and immunogenicity of the COVID-19 (SARS-CoV-2) vaccine candidates VBI-2902 and VBI-2905 in healthy adults.
Status: Completed
Phase 1
Study to evaluate the safety, tolerability, and immunogenicity of multivalent coronavirus vaccine candidate VBI-2901 (SARS-CoV-2, SARS-CoV, MERS-CoV), which has been designed to increase the breadth of protection against COVID-19 and related coronaviruses.
Status: Active, Not Recruiting
Cytomegalovirus
Prophylactic Vaccine Candidate : VBI-1501
Phase 1
Study to compare the safety and effectiveness of four different doses of VBI’s CMV vaccine candidate in healthy adults.
Status: Completed